RecruitingNot ApplicableNCT06910670

Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

Sponsor

Washington University School of Medicine

Enrollment

240 participants

Start Date

Apr 1, 2025

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer Cholangiocarcinoma Multiple Myeloma

Summary

The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing an expanded web-based tool to help cancer patients make more informed decisions about their care and understand their treatment options, specifically designed for people with certain cancers who may be underrepresented in research. **You may be eligible if...** - You are already enrolled in the WU-PE-CGS research study - You have been diagnosed with cholangiocarcinoma (bile duct cancer), OR you are African American and have been diagnosed with multiple myeloma or colorectal cancer (diagnosed at 65 or older) - You are 18 or older - You have access to a computer, tablet, or mobile device **You may NOT be eligible if...** - You are not already enrolled in the WU-PE-CGS study - You do not have access to a personal device to use the online tool - You are unable to understand the informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERStandard developed materials

Participants will be given the option to receive different types of results from genomic sequencing. The choices available to them will be explained by research staff following a script that describes what each type of result means. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information

OTHERGenetics Advisor Decision Aid

Participants will be given the option to receive different types of results from genomic sequencing. The participants will be given access to a web-based decision aid that elicits participants' values and preferences for receiving results from cancer genomic sequencing to guide them making a decision about what types of results they would like to receive. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues.